These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 32256205)

  • 1. A pooled analysis of the prognostic value of PD-L1 in melanoma: evidence from 1062 patients.
    Yang J; Dong M; Shui Y; Zhang Y; Zhang Z; Mi Y; Zuo X; Jiang L; Liu K; Liu Z; Gu X; Shi Y
    Cancer Cell Int; 2020; 20():96. PubMed ID: 32256205
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic value of programmed cell death ligand-1 expression in ovarian cancer: an updated meta-analysis.
    Piao J; Lim HJ; Lee M
    Obstet Gynecol Sci; 2020 May; 63(3):346-356. PubMed ID: 32489980
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic significance of programmed cell death-ligand 1 expression on circulating tumor cells in various cancers: A systematic review and meta-analysis.
    Ouyang Y; Liu W; Zhang N; Yang X; Li J; Long S
    Cancer Med; 2021 Oct; 10(20):7021-7039. PubMed ID: 34423578
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic and Clinicopathological Value of PD-L1 in Melanoma: A Meta-Analysis.
    Xu J; Wang F; Yan Y; Zhang Y; Du Y; Sun G
    Am J Med Sci; 2020 Jun; 359(6):339-346. PubMed ID: 32498941
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic Value of Programmed Cell Death Ligand-1 Expression in Nasopharyngeal Carcinoma: A Meta-Analysis of 1,315 Patients.
    Liu X; Shan C; Song Y; Du J
    Front Oncol; 2019; 9():1111. PubMed ID: 31709181
    [No Abstract]   [Full Text] [Related]  

  • 6. The Clinicopathologic and Prognostic Significance of Programmed Cell Death Ligand 1 (PD-L1) Expression in Patients With Prostate Cancer: A Systematic Review and Meta-Analysis.
    Li Y; Huang Q; Zhou Y; He M; Chen J; Gao Y; Wang X
    Front Pharmacol; 2018; 9():1494. PubMed ID: 30733677
    [No Abstract]   [Full Text] [Related]  

  • 7. Prognostic and Clinicopathological Significance of PD-L1 in Patients With Bladder Cancer: A Meta-Analysis.
    Zhu L; Sun J; Wang L; Li Z; Wang L; Li Z
    Front Pharmacol; 2019; 10():962. PubMed ID: 31616289
    [No Abstract]   [Full Text] [Related]  

  • 8. Prognostic significance of PD-L1 in solid tumor: An updated meta-analysis.
    Wang Q; Liu F; Liu L
    Medicine (Baltimore); 2017 May; 96(18):e6369. PubMed ID: 28471952
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The predictive implication of programmed cell death ligand 1 expression in extranodal natural killer/T-Cell lymphoma and its correlation with clinicopathological features: a systematic review and meta-analysis.
    Li W; Zheng Q; Luo X; Zhang X; Zheng X; Yang Y
    Transl Cancer Res; 2023 Aug; 12(8):2115-2127. PubMed ID: 37701117
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The prevalence and prognostic and clinicopathological value of PD-L1 and PD-L2 in renal cell carcinoma patients: a systematic review and meta-analysis involving 3,389 patients.
    Lu Y; Song Y; Xu Y; Ou N; Liang Z; Hu R; Zhang W; Kang J; Wang X; Liu L; Yang Y; Liu X
    Transl Androl Urol; 2020 Apr; 9(2):367-381. PubMed ID: 32420142
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic Value of Programmed Cell Death 1 Ligand-1 in Patients With Bone and Soft Tissue Sarcomas: A Systemic and Comprehensive Meta-Analysis Based on 3,680 Patients.
    Wang F; Yu T; Ma C; Yuan H; Zhang H; Zhang Z
    Front Oncol; 2020; 10():749. PubMed ID: 32582532
    [No Abstract]   [Full Text] [Related]  

  • 12. Prognostic and clinicopathological significance of PD-L1 in patients with renal cell carcinoma: a meta-analysis based on 1863 individuals.
    Wang Z; Peng S; Xie H; Guo L; Cai Q; Shang Z; Jiang N; Niu Y
    Clin Exp Med; 2018 May; 18(2):165-175. PubMed ID: 29362922
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Elevated PD-L1 expression predicts poor survival outcomes in patients with cervical cancer.
    Gu X; Dong M; Liu Z; Mi Y; Yang J; Zhang Z; Liu K; Jiang L; Zhang Y; Dong S; Shi Y
    Cancer Cell Int; 2019; 19():146. PubMed ID: 31143091
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic and Clinicopathological Role of PD-L1 in Endometrial Cancer: A Meta-Analysis.
    Lu L; Li Y; Luo R; Xu J; Feng J; Wang M
    Front Oncol; 2020; 10():632. PubMed ID: 32426281
    [No Abstract]   [Full Text] [Related]  

  • 15. Prognostic and Clinicopathological Value of Programmed Cell Death Ligand1 Expression in Patients With Small Cell Lung Cancer: A Meta-Analysis.
    Cai H; Zhang H; Jiang Y
    Front Oncol; 2020; 10():1079. PubMed ID: 32670887
    [No Abstract]   [Full Text] [Related]  

  • 16. Prognostic significance of programmed cell death ligand 1 expression in patients with ovarian carcinoma: A systematic review and meta-analysis.
    Huang LJ; Deng XF; Chang F; Wu XL; Wu Y; Diao QZ
    Medicine (Baltimore); 2018 Oct; 97(43):e12858. PubMed ID: 30412078
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic value of PD-L1 in esophageal squamous cell carcinoma: a meta-analysis.
    Guo W; Wang P; Li N; Shao F; Zhang H; Yang Z; Li R; Gao Y; He J
    Oncotarget; 2018 Mar; 9(17):13920-13933. PubMed ID: 29568405
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic and clinicopathological value of PD-L1 in colorectal cancer: a systematic review and meta-analysis.
    Yang L; Xue R; Pan C
    Onco Targets Ther; 2019; 12():3671-3682. PubMed ID: 31190869
    [No Abstract]   [Full Text] [Related]  

  • 19. The clinicopathological significance and prognostic value of programmed death-ligand 1 in prostate cancer: a meta-analysis of 3133 patients.
    Shen H; Liu J; Sun G; Yan L; Li Q; Wang Z; Xie L
    Aging (Albany NY); 2020 Dec; 13(2):2279-2293. PubMed ID: 33318295
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The prognostic significance of PD-L1 and PD-1 expression in patients with nasopharyngeal carcinoma: a systematic review and meta-analysis.
    Huang ZL; Liu S; Wang GN; Zheng SH; Ding SR; Tao YL; Chen C; Liu SR; Yang X; Chang H; Wang XH; Xia YF
    Cancer Cell Int; 2019; 19():141. PubMed ID: 31139018
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.